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66
The translation process of preclinical findings into clinical practice is fraught with time lags, steep 67 costs, and considerable failure rates [1] [2] [3] [4] [5] [6] [7] . It has been suggested that one of the problems 68 contributing to translational failures lies outside of clinical research itself, and instead originates 69 in the preclinical stage of research [8] [9] [10] . Translational barriers associated with preclinical 70 research include poor study design and reporting that make reproducibility difficult; biased 71 selection of animal models and small sample sizes which reduces inferential strength; and 72 publication bias which may distort evidence and justification to proceed to first-in-human trials [5, 73 6, 11]. In order to increase the chance of 'bench-to-bedside' translation success, various measures 74 to improve the state of preclinical research have been suggested [12, 13] . One measure is the 75 application of multicenter experimentation in preclinical studies, analogous to what is commonly 76 done in clinical trials [14, 15] . In both clinical and preclinical research, multicenter studies can 77 assess external validity and inherently test reproducibility, while also increasing efficiency in 78 meeting enrolment numbers [9] . In addition, rigorously designed and reported multicenter studies 79 offer the opportunity to enhance internal validity and increase transparency [16] . 80 
81
To improve the process of translation, multiple calls from the biomedical science community have 82 been made to adopt the multicenter preclinical approach [6, 12-14, 16, 17] . Some recent examples 83 have been published that exemplify the successful implementation of this approach [18] [19] [20] . As 84 interest in multicenter preclinical studies grows, and to demonstrate their value (if any), it is 85 imperative that a systematic evaluation should be performed of the studies conducted to date. This 86 will inform and optimize future multicenter preclinical studies by identifying knowledge gaps and 87 producing an evidence map of current practices and outcomes [5] [6] [7] . 88 
89
The objective of this systematic review was to identify and qualitatively summarize the preclinical 90 multicenter study literature. All multicenter in vivo preclinical studies of interventions were 91 included. We compared and contrasted the methods and organization of these experiments. Quality 92 of reporting, risk of bias, degree of collaboration, and barriers/enablers to multicenter study 93 conduct were assessed. Finally, we considered how results of these studies and the use of the 94 multicenter study design informed the translation of biomedical research.
95
Results
96
Search results and study characteristics 97 The database searches identified a total of 3095 papers after duplicates were removed (Fig 1) . 98 Two additional papers were identified through a search of references of included papers. After 99 title, abstract, and full-text screening twelve articles met eligibility criteria (Tables 1 and 2 ). The identified studies fell into six clinical domains: traumatic brain injury (n = 5), myocardial 106 infarction (n = 2), stroke (n = 2), diabetes (n = 1), traumatic injury (n = 1), and effects of stimulate 107 exposure (n = 1 centers involved, such as a coordinating center, data processing center, biomarker core, and a 116 pathology core. Five different species of animals were used by the studies: mice (n = 5), rats (n = 117 5), swine (n = 2), rabbits (n = 1), and dogs (n = 1). The median sample size was 135 (range 23-384   118 animals), and a total 1794 animals were used across the twelve studies, 93% of which were lab 119 rodents (mice and rats).
120
Reported outcomes Table) .
136
Risk of Bias
137
None of the 12 studies (0%) were considered low risk of bias across all ten domains ( had high risk of bias for other sources of bias due to potential industry-related influences (Table   144 3). The four 'other sources' of risk of bias assessments for each study is found in the supporting 145 information (S3 Table) . Random Housing: Low risk = Animal cages were randomly placed within an animal room/facility, Unclear = Housing placement unreported, High risk = Animals place in non-random arrangement in animal room/facility. Blinding of Outcome Assessment: Low risk = Outcome assessors were blinded to the study groups when assessing endpoints/animals Unclear = Insufficient information to determine if outcome assessors were blinded during assessment. High Risk = Outcome assessors not blinded to the study groups. Incomplete Outcome Data: Low risk = N values were consistent between methods and results for the outcomes. Unclear = N value was either not presented in the methods or in the results, and therefore there is insufficient information to permit judgement. High risk = N values were not consistent between methods and results for the outcomes. Selective Reporting: Low risk = The methods section indicated pre-specified outcome measure. Unclear: Was not clear about the pre-specified primary endpoints and outcome results. High risk = The outcome was presented in the results but not pre-specified in the methods section. + other sources include funding influences, conflicts of interest, contamination, unit of analysis errors 1 Method of randomization not specified 2 Some centers used appropriate randomization where others used pseudo-randomization 3 Assessed as high because one arm of the study was inadvertently unblinded
147
Reporting quality brain injury studies included preclinical in the paper title. Reporting assessment for all twenty-162 nine items across the twelve studies can be found in the supporting information (S4 Table) . 
Degree of collaboration
173
Overall, the twelve studies scored medium to high in the degree of collaboration ( 
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The species-specific differences in factor activities will require ongoing investigation to ensure full safety and efficacy. Our future investigations will include a comprehensive evaluation of the effects of the lyophilization process on coagulation properties of the LP. 
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Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
21-22
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
22-23, 37
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). 23
Data collection process 10
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
23-25
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 23
Risk of bias in individual studies
12
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
